
Charles River Laboratories International CRL
$ 210.54
-0.57%
Quarterly report 2025-Q3
added 11-05-2025
Charles River Laboratories International Total Non Current Liabilities 2011-2026 | CRL
Annual Total Non Current Liabilities Charles River Laboratories International
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 2.35 B | 1.98 B | 1.42 B | 1.44 B | 1.02 B | 917 M | 757 M | 643 M | 814 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.35 B | 643 M | 1.26 B |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
4.17 M | $ 3.05 | -1.62 % | $ 99 K | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Brainsway Ltd.
BWAY
|
7.58 M | $ 23.39 | -2.74 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
61.1 M | $ 34.5 | 2.16 % | $ 371 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
16.4 M | $ 1.24 | -15.65 % | $ 1.58 M | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 39.73 | 1.44 % | $ 1.1 B | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
3.56 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
26.9 B | $ 219.15 | -0.14 % | $ 160 B | ||
|
Exact Sciences Corporation
EXAS
|
981 M | $ 102.44 | 0.13 % | $ 19 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 26.14 | -0.38 % | $ 790 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
Guardant Health
GH
|
91.4 M | $ 113.64 | 2.86 % | $ 13.9 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
1.15 B | $ 73.4 | -0.81 % | $ 28.3 B | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 20.69 | -0.53 % | $ 1.11 B | ||
|
Celcuity
CELC
|
69.2 K | $ 109.42 | -2.41 % | $ 4.32 B | ||
|
DarioHealth Corp.
DRIO
|
25.8 M | $ 9.94 | -3.54 % | $ 282 M | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 66.97 | 0.44 % | $ 4.63 B | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
2.04 B | $ 145.56 | -2.76 % | $ 23.1 B | ||
|
NeoGenomics
NEO
|
434 M | $ 12.04 | -2.9 % | $ 1.52 B | ||
|
QIAGEN N.V.
QGEN
|
1.58 B | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
13 B | $ 231.17 | -1.83 % | $ 41.9 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 585.64 | -1.25 % | $ 18.1 B | ||
|
Personalis
PSNL
|
639 K | $ 9.43 | -5.42 % | $ 559 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 186.85 | 2.49 % | $ 20.7 B | ||
|
Biodesix
BDSX
|
62.1 M | $ 9.94 | 2.85 % | $ 1.29 B | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
1.9 M | $ 24.53 | 1.11 % | $ 31.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 271.48 | 0.62 % | $ 22.8 B | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 381.85 | -0.79 % | $ 29.3 B | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 180.78 | -2.75 % | $ 14.9 B | ||
|
IDEXX Laboratories
IDXX
|
630 M | $ 674.26 | -0.36 % | $ 55.6 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.08 B | $ 28.74 | -1.74 % | $ 20 B | ||
|
Agilent Technologies
A
|
3.29 B | $ 133.38 | 0.11 % | $ 40.5 B | ||
|
Biomerica
BMRA
|
1.57 M | $ 2.36 | -1.26 % | $ 5.42 M |